Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

ZYDUSLIFE NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
1.1L Cr
Volatility
Moderate
P/E Ratio
22.24
EBITDA
₹8,985 Cr
Return on Equity
16.99%
Debt to Equity
0.46
Book Value
₹271.78
EPS
₹41.43
52W High
₹1,181.5
52W Low
₹835.5

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Lifesciences Ltd insights

46 extracted metrics + investor summaries across FY05–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Growth Rate

Revenue Growth
17.64% ↗
Net Income Growth
8.92% ↘
Cash Flow Change
-68.79% ↘
ROE
-2.97% ↘
ROCE
-12.51% ↘
EBITDA Margin (Avg.)
4.20% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
AI opinion · based on fundamentals
Risk medium

Zydus Lifesciences is a Rs 1.12 lakh crore market cap pharmaceutical company trading at a PE of 21.8x with FY25 revenue of Rs 23,242 crore (up 19% YoY) and net profit of Rs 4,745 crore (up 23% YoY). The company maintains a net cash position (net debt-to-equity of -0.20x) and has delivered consistent ROE of ~21% over 3, 5, and 10-year periods.

Bull Case 8
  • Strong revenue growth with FY25 top-line at Rs 23,242 crore, up 19% YoY, accelerating from 13.4% growth in FY24
  • Compounded profit CAGR of 32% over 3 years significantly outpaces sales growth of 16%, indicating improving operating leverage
  • Net cash balance sheet with net debt-to-equity of -0.20x and net cash of Rs 4,884 crore as of March 2025, providing financial flexibility for R&D and acquisitions
  • Consistent ROE of 21% maintained across 3-year, 5-year, and 10-year periods, reflecting disciplined capital allocation
  • US business delivered 31% revenue growth to Rs 2,410 crore in FY25 with quarterly run-rate of ~$285 million, driven by new product launches
  • EBITDA margin expanded to 30.4% in FY25 (from 27.5% in FY24), a 290 bps improvement demonstrating pricing power and cost efficiency
  • Novel pipeline advancing with Usnoflast receiving both Orphan Drug Designation and Fast Track Designation from USFDA for ALS treatment, offering potential seven-year marketing exclusivity
  • PE of 21.8x is reasonable relative to 17% TTM profit growth and 19% revenue growth, suggesting earnings growth is keeping pace with valuation
Bear Case 8
  • Dividend yield of only 0.09% is minimal for a profitable company generating Rs 4,745 crore in net profit, indicating limited shareholder returns via dividends
  • USFDA warning letter issued in August 2024 for the Jarod facility following April 2024 inspection, creating regulatory risk for future ANDA approvals from that site
  • Q4 FY25 net profit declined 1% YoY to Rs 1,170 crore despite 18% revenue growth, signaling potential margin pressure in the most recent quarter
  • Gross debt increased to Rs 3,213 crore in FY25, and while net cash is still positive, the rising leverage trend warrants monitoring
  • US generics business faces structural price erosion risk; Q3 FY25 US revenue was flat QoQ at $285 million vs $288 million in Q2 FY25, showing sequential momentum stalling
  • India formulations grew only 5% YoY in Q3 FY25 versus estimates of 9%, underperforming the broader Indian pharma market growth rate of ~8-10%
  • Stock CAGR of 17% over 1 year and 20% over 3 years has run ahead of 10-year earnings CAGR of 11%, suggesting some valuation expansion already priced in
  • High dependence on US market for growth exposes the company to regulatory actions, patent litigation risks, and currency fluctuation impact on dollar-denominated revenues

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Headwinds 2
  • ₹108.54 mn stamp duty demand Jul 29

    Gujarat authorities issued a ₹108.54 million stamp duty demand over the Sterling Biotech asset acquisition, citing valuation differences and incomplete registration details.

  • Ahmedabad ops halted by rains Jul 25

    Operations at Ahmedabad facilities were temporarily suspended due to heavy rains and waterlogging before resuming on July 25, 2026.

Positives 2
  • Record FY26 revenue ₹271.5 bn Jul 12

    Consolidated revenue grew 17% YoY to ₹271.5 billion with EBITDA margin of 31.2% and PAT of ₹54,564 million (+15% YoY) in FY26.

  • USFDA nod with 180-day exclusivity Aug 4

    Secured final USFDA approval for Indocyanine Green for Injection with 180-day CGT exclusivity, targeting a USD 125.8 mn US market and adding to 445 cumulative US approvals.

Neutral 3
  • Q1 FY27 results on Aug 11 Jul 30

    Board meeting scheduled for August 11, 2026 to declare Q1 FY27 results; Dr. Sharvil Patel will host the post-results webinar at 4:00 PM IST.

  • Investor conferences on Aug 13 Aug 4

    Zydus will present at both Emkay Confluence 2026 and Equirus Annual India Conference on August 13, 2026 to engage investors on strategic outlook.

  • 36% renewable energy in FY26 Jul 10

    Business Responsibility and Sustainability Report for FY26 highlights 36% renewable energy usage and total emissions of 2,89,737 tCO2e.

TL;DR: Zydus Lifesciences delivered a strong FY26 with record revenue growth of 17% YoY and healthy 31.2% EBITDA margins, supported by continued US pipeline expansion (445 approvals). Risks are minor — a ₹108.54 mn stamp duty demand and brief weather disruption — neither materially impactful. The trend is positive heading into Q1 FY27 results on Aug 11, with the 180-day exclusivity on Indocyanine Green providing near-term US revenue upside.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
5,011
5,140
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
Expenses
3,755
3,634
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
Operating Profit
1,256
1,505
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
OPM %
25%
29%
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
Other Income
-566
21
53
60
160
63
68
57
-139
155
75
26
-263
Interest
28
18
9
20
35
32
25
32
77
85
101
130
123
Depreciation
179
180
184
195
205
215
234
229
238
238
302
360
508
PBT
484
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
Tax %
28%
16%
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
Net Profit
358
1,134
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
EPS in Rs
2.93
10.74
7.91
7.8
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
8,651
9,427
9,376
11,905
13,166
14,253
15,102
15,265
17,237
19,547
23,242
27,148
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,758
11,923
13,378
14,163
16,183
18,673
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,344
3,342
3,860
5,384
7,058
8,475
OPM %
20%
25%
20%
24%
23%
20%
22%
22%
22%
28%
30%
31%
Other Income
45
112
127
111
183
-264
-171
2,581
-422
293
50
-7
Interest
68
53
45
91
194
342
164
127
130
81
166
439
Depreciation
287
292
373
539
599
696
725
713
723
764
916
1,408
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,285
5,084
2,585
4,832
6,027
6,621
Tax %
18%
8%
8%
24%
22%
21%
6%
10%
23%
20%
23%
24%
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
EPS in Rs
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,584
4,221
1,195
804
3,213
12,496
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,189
6,421
6,851
8,201
9,523
11,065
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,253
11,521
12,368
13,134
24,106
CWIP
798
951
1,543
1,527
837
742
783
661
1,201
2,423
2,692
3,698
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,412
7,540
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,451
15,328
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,505
3,293
2,104
2,689
3,228
6,781
2,117
Investing
-465
-860
-2,872
-974
-3,977
-1,012
-835
1,137
1,178
-1,492
-8,363
-7,895
Financing
-351
-935
2,316
52
1,885
-1,094
-2,549
-868
-4,400
-1,810
1,995
5,807
Net Cash Flow
178
99
756
-3
-811
399
-90
2,373
-534
-75
414
28
Free Cash Flow
498
936
-1,623
-116
236
1,617
2,446
1,050
1,697
2,345
5,139
-530
CFO/OP
79
109
81
54
65
100
109
83
85
84
122
44
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
76
80
94
97
64
73
Inventory Days
175
158
193
211
208
207
227
245
197
202
227
282
Days Payable
125
154
165
167
149
151
155
141
123
125
131
142
Cash Conversion Cycle
118
71
116
142
169
150
148
184
168
175
160
212
Working Capital Days
6
-1
-34
17
10
-19
-6
19
70
88
3
-40
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Shareholding Pattern

As of Jun 2026
Promoters 75.01%
DIIs 11.27%
FIIs 6.88%
Public 5.45%
Others 1.38%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
74.88%
74.88%
74.88%
74.88%
74.88%
74.88%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.99%
74.99%
74.99%
75.00%
75.00%
75.01%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
5.72%
5.59%
7.52%
7.53%
7.32%
7.13%
7.34%
7.06%
6.95%
6.88%
DIIs
11.11%
10.43%
11.22%
11.78%
12.78%
11.92%
12.94%
13.69%
13.60%
13.23%
13.09%
12.79%
12.63%
12.64%
10.65%
10.65%
11.01%
11.13%
10.86%
11.09%
11.20%
11.27%
Government
0.19%
0.07%
0.07%
0.07%
0.08%
0.08%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
6.16%
7.31%
7.38%
7.40%
7.81%
8.02%
7.60%
7.04%
6.42%
5.97%
5.67%
5.60%
5.29%
5.37%
5.48%
5.47%
5.41%
5.46%
5.49%
5.54%
5.54%
5.45%
Others
7.66%
7.32%
6.44%
5.87%
4.46%
5.11%
4.48%
4.29%
5.00%
5.82%
6.26%
6.63%
1.38%
1.43%
1.37%
1.36%
1.28%
1.28%
1.32%
1.31%
1.32%
1.38%
No. of Shareholders
0
2,23,384
3,31,155
3,51,595
3,70,931
4,08,017
4,55,624
4,08,231
3,70,396
3,11,764
2,97,953
3,06,495
2,94,324
3,36,309
3,70,863
3,65,356
3,71,619
3,86,127
3,96,105
4,03,266
4,18,314
4,03,889

Documents

1
Concall - Mar 2017 Mar 2017
2
Concall - Sep 2017 Sep 2017
3
Concall - Nov 2017 Nov 2017
4
Concall - Jun 2018 Jun 2018
5
Concall - Jan 2019 Jan 2019

Frequently Asked Questions about Zydus Lifesciences Ltd

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise...
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: ZYDUSLIFE and BSE: 532321. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of approximately ₹111259.29 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Zydus Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 22.24. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹835.5 and a high of ₹1,181.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Zydus Lifesciences Ltd pay dividends?
Yes, Zydus Lifesciences Ltd has a dividend yield of 0.09%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a Return on Equity (ROE) of 16.99%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Zydus Lifesciences Ltd on Tapetide?
On Tapetide, you can view Zydus Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Website zyduscadila.com
CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 2000-04-18
Face Value ₹ 1
Issued Size 1,00,62,33,990

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List